Table 2 Risk of breast cancer-specific death in 584 Nordic carriers of BRCA2 mutations according to key tumour characteristics, oophorectomy and treatment.

From: Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status

  

Univariate

disease-specific survival

Multivariatea

disease-specific survival

  

HR (95% CI)

P value

HR (95% CI)

P value

Year of diagnosis

Continuous

0.96 (0.94–0.98)

<0.001

0.98 (0.95–1.01)

0.16

Size >20–≤50 vs ≤20 mm

244 vs 311

1.73 (1.23–2.45)

<0.01

1.57 (1.07–2.32)

0.02

>50 vs ≤20 mm

29 vs 311

2.78 (1.49–5.19)

<0.01

2.65 (1.32–5.34)

0.01

Lymph node status (pos/neg)

314 vs 270

1.49 (1.06–2.09)

0.02

1.65 (1.04–2.62)

0.03

Grade 2 + 3 vs 1

472 vs 61

0.65 (0.40–1.05)

0.08

0.71 (0.43–1.16)

0.17

ER+ 0–5 y vs ER− b

354 vs 126

0.42 (0.23–0.77)

<0.01

0.49 (0.26–0.93)

0.03

ER + 5+ y vs ER− c

377 vs 126

1.60 (0.94–2.74)

0.09

1.91 (1.07–3.39)

0.03

Oophorectomyd

176 vs 408

0.39 (0.24–0.64)

<0.001

0.67 (0.38–1.20)

0.18

Mastectomy vs lumpectomy

369 vs 215

1.34 (0.92–1.93)

0.12

0.94 (0.59–1.51)

0.81

Adjuvant chemotherapy, any

383 vs 201

0.75 (0.54–1.05)

0.01

0.65 (0.43–1.00)

0.05

Radiation

404 vs 180

1.02 (0.72–1.45)

0.90

1.08 (0.70–1.65)

0.74

Endocrine therapy, any

345 vs 239

0.74 (0.53–1.04)

0.08

0.84 (0.53–1.32)

0.44

Mutation location, OCCRs + BCCRs vs “Other”e

391 vs 193

1.58 (1.04–2.41)

0.03

1.26 (0.76–2.09)

0.38

  1. aAdjusted also for country, prophylactic mastectomy and unknown grade.
  2. bOestrogen-receptor positive up to 5 years after diagnosis vs oestrogen-receptor negative.
  3. cOestrogen-receptor positive 5 years or more after diagnosis vs oestrogen-receptor negative.
  4. dBefore or within 2 years from diagnosis.
  5. eOther locations than ovarian cancer cluster regions (OCCRs) or breast cancer cluster regions (BCCRs).
Back to article page